Nucleoporin 98 (NUP98) mRNA (NUP98 mRNA)

Nucleoporin 98 (NUP98) mRNA is the transcript encoding a key structural and functional component of the nuclear pore complex, which regulates the bidirectional trafficking of macromolecules between the nucleus and cytoplasm (UniProt P52948). In the context of oncology, NUP98 mRNA is a significant therapeutic target because the NUP98 gene frequently undergoes chromosomal translocations, leading to the production of chimeric fusion mRNAs such as NUP98-HOXA9 or NUP98-NSD1 (PubMed: 32814069). These fusion transcripts encode oncoproteins that act as aberrant transcription factors, promoting self-renewal in hematopoietic stem cells and driving the development of aggressive leukemias like acute myeloid leukemia (AML) (PubMed: 28232591). Therapeutic strategies targeting NUP98 mRNA involve the use of antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) designed to induce the degradation of these oncogenic transcripts, thereby preventing the translation of the fusion proteins (PubMed: 16280657). While direct mRNA-targeting agents remain largely in the preclinical phase, the presence of NUP98 rearrangements serves as a critical biomarker for patient stratification and the use of emerging therapies like Menin inhibitors that target the resulting protein complexes (PubMed: 31511318).

Other names

NUP98NUP96AVDNUP196Nucleoporin 98kDa mRNANUP98-HOXA9 fusion mRNA

RNA interference or antisense-mediated degradation of the NUP98 or NUP98-fusion transcript to prevent translation of oncogenic proteins.